NUCKS promotes cell proliferation and suppresses autophagy through the mTOR-Beclin1 pathway in gastric cancer

Table 1 Correlation of NUCKS expression with Clinicopathological variables in TCGA data sets

Clinicopathological features		Cases	NUCKS expression				F	P
Clinicopathological features		Cases	Low	%	High	%	F	P
Age	< 60	121	47	38.8	74	61.2	8.520	0.004
Age	≥60	286	156	54.5	130	45.5	8.520	0.004
Gender	Male	144	77	53.5	67	46.5	1.150	0.284
Gender	Female	263	126	47.9	137	52.1	1.150	0.284
H. pylori infection	Negative	150	65	43.3	85	56.7	0.586	0.445
H. pylori infection	Positive	19	10	52.6	9	47.4	0.586	0.445
Depth of invasion	T1	22	13	59.1	9	40.9	4.210	0.041
	T2	69	40	58.0	29	42.0
	T3	181	86	47.5	95	52.5
	T4	33	17	51.5	16	48.5
	T4a	48	20	41.7	28	58.3
	T4b	24	10	41.7	14	58.3
Lymph node metastasis	N0	123	66	53.7	57	46.3	6.040	0.014
	N1	108	63	58.3	45	41.7
	N2	83	40	48.2	43	51.8
	N3	74	27	36.5	47	63.5
Distant metastasis	M0	358	179	50.0	179	50.0	1.687	0.195
Distant metastasis	M1	27	17	63.0	10	37.0	1.687	0.195
Histologic Grade	G1	10	4	40.0	6	60.0	0.534	0.462
	G2	150	81	54.0	69	46.0
	G3	238	114	47.9	124	52.1
Grade	Stage I	59	33	55.9	26	44.1	0.526	0.469
	Stage II	126	68	54.0	58	46.0
	Stage III	156	63	40.4	93	59.6
	Stage IV	42	27	64.3	15	35.7
Lauren’s histological type	Intestinal type	82	49	59.8	33	40.2	4.475	0.036
Lauren’s histological type	Diffuse type	66	28	42.4	38	57.6	4.475	0.036
Days to new tumor event after initial treatment	< 326	31	15	48.4	16	51.6	0.063	0.803
Days to new tumor event after initial treatment	≥326	31	14	45.2	17	54.8	0.063	0.803
Neoplasm status	Tumor free	185	102	55.1	83	44.9	3.005	0.084
Neoplasm status	With tumor	74	32	43.2	42	56.8	3.005	0.084

ISSN: 1756-9966